<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00677378</url>
  </required_header>
  <id_info>
    <org_study_id>CHW 06/34</org_study_id>
    <nct_id>NCT00677378</nct_id>
  </id_info>
  <brief_title>Transient Receptor Potential Vanilloid One (TRPV1) Receptor Expression in Children With Retrosternal Pain</brief_title>
  <acronym>TRPV1</acronym>
  <official_title>Capsaicin-sensitive Transient Receptor Potential Vanilloid One (TRPV1) and Tyrosine Kinase (TrkA) Receptor Expression in Children With Retrosternal Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical College of Wisconsin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We would like to evaluate the changes in nerve innervation and TRPV1 receptor expression
      along with microscopic changes associated with heart burn and abdominal pain
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 5% of children between 10-17 years of age report symptoms of heart burn,
      epigastric pain or regurgitation. This study will evaluate the changes in nerve innervation
      and TRPV1 receptor expression in children having upper endoscopy for evaluation of heart burn
      and abdominal pain.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To characterize the TRPV1 expression in the esophageal mucosa of children with esophagitis and to correlate the TRPV1 expression with severity of mucosal inflammation and microscopic changes.</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">77</enrollment>
  <condition>Epigastric Pain</condition>
  <condition>Retrosternal Pain</condition>
  <condition>Esophagitis</condition>
  <condition>Gastrointestinal Symptoms</condition>
  <arm_group>
    <arm_group_label>EXPERIMENTAL</arm_group_label>
    <description>Children undergoing an endoscopy for retrosternal chest pain, epigastric pain, regurgitation, heart burn or dyspepsia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CONTROL</arm_group_label>
    <description>Children undergoing an endoscopy for reasons not stated in the experimental group condition (i.e. celiac disease, rectal bleeding, polyps, weight loss, malabsorption).</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      We are collecting a single mucosal biopsy during an endoscopy procedure.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Children undergoing an endoscopy procedure for gastrointestinal symptoms and chest pain or
        reasons other than those listed in the exclusion criteria.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Retrosternal and/or epigastric pain and esophagitis

          -  Retrosternal and/or epigastric pain but no macroscopic or microscopic esophagitis

          -  Gastrointestinal symptoms such as diarrhea, regurgitation, rumination, vomiting,
             feeding aversion, non-organic failure to thrive, celiac disease with no macroscopic or
             microscopic esophageal inflammation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manu Sood, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical College of Wisconsin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Nelson SP, Chen EH, Syniar GM, Christoffel KK. Prevalence of symptoms of gastroesophageal reflux during childhood: a pediatric practice-based survey. Pediatric Practice Research Group. Arch Pediatr Adolesc Med. 2000 Feb;154(2):150-4.</citation>
    <PMID>10665601</PMID>
  </reference>
  <reference>
    <citation>El-Serag HB, Bailey NR, Gilger M, Rabeneck L. Endoscopic manifestations of gastroesophageal reflux disease in patients between 18 months and 25 years without neurological deficits. Am J Gastroenterol. 2002 Jul;97(7):1635-9.</citation>
    <PMID>12135011</PMID>
  </reference>
  <reference>
    <citation>Carlsson R, Galmiche JP, Dent J, Lundell L, Frison L. Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: a meta-analysis of long-term omeprazole trials. Aliment Pharmacol Ther. 1997 Jun;11(3):473-82.</citation>
    <PMID>9218069</PMID>
  </reference>
  <reference>
    <citation>Sarkar S, Hobson AR, Furlong PL, Woolf CJ, Thompson DG, Aziz Q. Central neural mechanisms mediating human visceral hypersensitivity. Am J Physiol Gastrointest Liver Physiol. 2001 Nov;281(5):G1196-202.</citation>
    <PMID>11668028</PMID>
  </reference>
  <reference>
    <citation>Mehta AJ, De Caestecker JS, Camm AJ, Northfield TC. Sensitization to painful distention and abnormal sensory perception in the esophagus. Gastroenterology. 1995 Feb;108(2):311-9.</citation>
    <PMID>7835571</PMID>
  </reference>
  <reference>
    <citation>Cervero F. Visceral hyperalgesia revisited. Lancet. 2000 Sep 30;356(9236):1127-8.</citation>
    <PMID>11030288</PMID>
  </reference>
  <reference>
    <citation>Faussone-Pellegrini MS, Taddei A, Bizzoco E, Lazzeri M, Vannucchi MG, Bechi P. Distribution of the vanilloid (capsaicin) receptor type 1 in the human stomach. Histochem Cell Biol. 2005 Jul;124(1):61-8. Epub 2005 Jul 22.</citation>
    <PMID>16041554</PMID>
  </reference>
  <reference>
    <citation>Cervero F, Laird JM. Understanding the signaling and transmission of visceral nociceptive events. J Neurobiol. 2004 Oct;61(1):45-54. Review.</citation>
    <PMID>15362152</PMID>
  </reference>
  <reference>
    <citation>Yiangou Y, Facer P, Dyer NH, Chan CL, Knowles C, Williams NS, Anand P. Vanilloid receptor 1 immunoreactivity in inflamed human bowel. Lancet. 2001 Apr 28;357(9265):1338-9.</citation>
    <PMID>11343743</PMID>
  </reference>
  <reference>
    <citation>Chan CL, Facer P, Davis JB, Smith GD, Egerton J, Bountra C, Williams NS, Anand P. Sensory fibres expressing capsaicin receptor TRPV1 in patients with rectal hypersensitivity and faecal urgency. Lancet. 2003 Feb 1;361(9355):385-91.</citation>
    <PMID>12573376</PMID>
  </reference>
  <reference>
    <citation>Lewin GR, Mendell LM. Nerve growth factor and nociception. Trends Neurosci. 1993 Sep;16(9):353-9. Review.</citation>
    <PMID>7694405</PMID>
  </reference>
  <reference>
    <citation>Anand P, Terenghi G, Warner G, Kopelman P, Williams-Chestnut RE, Sinicropi DV. The role of endogenous nerve growth factor in human diabetic neuropathy. Nat Med. 1996 Jun;2(6):703-7.</citation>
    <PMID>8640566</PMID>
  </reference>
  <reference>
    <citation>Micera A, Puxeddu I, Aloe L, Levi-Schaffer F. New insights on the involvement of Nerve Growth Factor in allergic inflammation and fibrosis. Cytokine Growth Factor Rev. 2003 Oct;14(5):369-74. Review.</citation>
    <PMID>12948520</PMID>
  </reference>
  <reference>
    <citation>Anand P, Pandya S, Ladiwala U, Singhal B, Sinicropi DV, Williams-Chestnut RE. Depletion of nerve growth factor in leprosy. Lancet. 1994 Jul 9;344(8915):129-30.</citation>
    <PMID>7912365</PMID>
  </reference>
  <reference>
    <citation>Indo Y. Genetics of congenital insensitivity to pain with anhidrosis (CIPA) or hereditary sensory and autonomic neuropathy type IV. Clinical, biological and molecular aspects of mutations in TRKA(NTRK1) gene encoding the receptor tyrosine kinase for nerve growth factor. Clin Auton Res. 2002 May;12 Suppl 1:I20-32. Review.</citation>
    <PMID>12102460</PMID>
  </reference>
  <reference>
    <citation>March JS, Parker JD, Sullivan K, Stallings P, Conners CK. The Multidimensional Anxiety Scale for Children (MASC): factor structure, reliability, and validity. J Am Acad Child Adolesc Psychiatry. 1997 Apr;36(4):554-65.</citation>
    <PMID>9100431</PMID>
  </reference>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2008</study_first_submitted>
  <study_first_submitted_qc>May 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2008</study_first_posted>
  <last_update_submitted>October 21, 2015</last_update_submitted>
  <last_update_submitted_qc>October 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical College of Wisconsin</investigator_affiliation>
    <investigator_full_name>Manu Sood</investigator_full_name>
    <investigator_title>Chief, Associate Professor</investigator_title>
  </responsible_party>
  <keyword>TRPV1</keyword>
  <keyword>Nerve growth factor</keyword>
  <keyword>Capsaicin</keyword>
  <keyword>TrkA</keyword>
  <keyword>Retrosternal pain</keyword>
  <keyword>Epigastric pain</keyword>
  <keyword>Esophagitis</keyword>
  <keyword>Gastrointestinal symptoms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophagitis</mesh_term>
    <mesh_term>Chest Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capsaicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

